IP Library Granted Patent US 6,995,158
Granted Patent B2
US 6,995,158 · App. 10/377,618 · Granted Feb 7, 2006

Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (BH4) or derivatives thereof used for the treating or preventing cardiovascular or neurological disorders by modulation of the activity of nitric oxide synthase (NOS)

Assignee: Eprov A.G.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,995,158
App. No.
10/377,618
Granted
Feb 7, 2006
Kind
B2
Abstract

The invention relates to the uses of at least folic acid or a folate and tetrahydrobiopterin (BH 4 ) or derivative thereof for treating or preventing cardiovascular of neurological disorders by modulation of the activity of nitric oxide synthase (NOS).

Claims (20)

1. A pharmaceutical composition comprising

(1) folic acid or a folate;

(2) tetrahydrobiopterin (BH 4 );

(3) arginine

wherein arginine is present in a unit dosage of 1 mg to 250 mg.

2. The composition as defined in claim 1 wherein folic acid or a folate is folic acid (pteroylmonoglutamate), one or more of the folylpolyglutamates, compounds in which the pyrazine ring of the pterin moiety of folic acid or of the folylpolyglutamates is reduced to give dihydrofolates or tetrahydrofolates, or derivatives of all the preceding compounds in which the N-5 or N-10 positions carry one carbon units at various levels of oxidation, or salt.

3. The composition as defined in claim 1 wherein folate is the natural diastereoisomer of folate.

4. The composition as defined in claim 1 wherein folate is

dihydrofolic acid,

tetrahydrofolic acid,

5-methyltetrahydrofolic acid,

5,10-methylenetetrahydrofolic acid,

5,10-methenyltetrahydrofolic acid,

5,10-formiminotetrahydrofolic acid,

5-formyltetrahydrofolic acid (leucovorin),

10-formyltetrahydrofolic acid,

10-methyltetrahydrofolic acid,

pharmaceutically compatible salts thereof, or a combination of two or more thereof.

5. A composition according to claim 1 , in combination with at least one active substance or at least one adjuvant substance.

6. A composition according to claim 5 , wherein the active substance is pharmaceutically compatible active substance.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME SHOULD READ: EPROVA A.G. PREVIOUSLY RECORDED ON REEL 030098 FRAME 0596. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE NAME EPROV A.G. CONTAINED A SPELLING ERROR AND SHOULD BE CORRECTED TO READ EPROVA A.G.. Recorded Mar 29, 2013
From: RABELINK, TON J.; MOSER, RUDOLF
To: EPROVA A.G.
Reel/Frame 030111/0799 →
CHANGE OF NAME Recorded Mar 28, 2013
From: EPROVA A.G.
To: MERCK EPROVA AG
Reel/Frame 030102/0592 →
MERGER Recorded Mar 28, 2013
From: MERCK EPROVA AG
To: MERCK & CIE KG
Reel/Frame 030102/0669 →
CHANGE OF NAME Recorded Mar 28, 2013
From: MERCK & CIE KG
To: MERCK & CIE
Reel/Frame 030102/0827 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2013
From: RABELINK, TON J.; MOSER, RUDOLF
To: EPROV A.G.
Reel/Frame 030098/0596 →
Continuity (2)
Division 0958830100 · Jun 7, 2000
Related Publication 20030216400A1 · Nov 20, 2003